György M. Keserű obtained his Ph.D. at Budapest, Hungary and joined Sanofi heading a chemistry research lab. He moved to Gedeon Richter in 1999, and he was appointed as the Head of Discovery Chemistry in 2007. He contributed to the discovery of the antipsychotic Vraylar® (cariprazine) that has been approved and marketed from 2016 in US and EU. He served as a director general of the Research Centre for Natural Sciences at the Hungarian Academy of Sciences. From 2015 he is heading the Medicinal Chemistry Research Group. György published over 300 papers, and he is a co-inventor in 21 patents. He was awarded by the prestigious Overton and Meyer Award of the European Federation of Medicinal Chemistry and has been elected as member of the Hungarian Academy of Sciences and Academia Europeae.
Prof. Dr. Keserű György
Scientific and Innovation Advisory Board